
|Videos|June 16, 2017
Comprehensive Genomic Profiling With Loss of Heterozygosity for Ovarian Cancer Treatment
Author(s)Julia Elvin, MD, PhD
Julia Elvin, MD, PhD, vice president and senior associate medical director, Foundation Medicine, discusses a study of comprehensive genomic profiling with loss of heterozygosity to identify therapeutically relevant subsets of ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































